AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Chairman’s report (verbal update)
5. Minutes of previous meeting

6. Appraisal 1
   Midazolam (Buccolam®) for the treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). Buccolam must only be used by parents/carers where the patient has been diagnosed to have epilepsy. For infants between 3-6 months of age treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available.

7. Appraisal 2
   Fluorouracil/salicylic acid (Actikerall®) for topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (grade I/II) in immunocompetent adult patients

8. Appraisal 3
   Atorvastatin (Lipitor®) chewable tablets as an adjunct to diet for reduction of elevated total cholesterol (total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and triglycerides in adults, adolescents and children aged 10 years or older with primary hypercholesterolaemia including familial hypercholesterolaemia (heterozygous variant) or combined (mixed) hyperlipidaemia (corresponding to Types IIa and IIb of the Fredrickson classification) when response to diet and other non pharmacological measures is inadequate.

   - To reduce total-C and LDL-C in adults with homozygous familial hypercholesterolaemia as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailable.

   - Prevention of cardiovascular events in adult patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factors.

9. Date of next meeting - Wednesday, 20th June 2012 in Cardiff

Enclosure

1/AWMSG/0512
2/AWMSG/0512 Appendices
3/AWMSG/0512 Appendices
4/AWMSG/0512 Appendices